Synonyms: Anti-FLJ14062; Anti-MTERFD3
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Mitochondrial transcription termination factor 3 is also known as CGI-12 and MTERFD1. Tissue-specific inactivation of this gene in the heart causes aberrant mitochondrial DNA (mtDNA) transcription and severe respiratory chain deficiency. It binds the mtDNA promoter region and depletion of MTERF3 increases transcription initiation on both mtDNA strands. This mitochondrial protein acts as a specific repressor of mammalian mtDNA transcription initiation in vivo. The over-expression of epitope-tagged MTERFD3 leads to modest mtDNA copy-number depletion and an accumulation of specific mtDNA replication intermediates indicating an impairment of the terminal steps of replication.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC